A study of suvecaltamide in the treatment of moderate to severe residual tremor from Parkinson's disease (H-54088)
Description
Content
A 17-Week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, multicenter study of the efficacy and safety of suvecaltamide in the treatment of moderate to severe residual tremor in participants with Parkinson's disease
The purpose of this study is to evaluate suvecaltamide in Parkinson’s disease participants. Suvecaltamide is an experimental drug, which means that the Food and Drug Administration (FDA) has not approved it for the treatment of Parkinson’s disease or any other indication.
Contact
Phone 1: 713–798–5989
IRB: H-54088
Status:
Active
Created:
